Fiche centre
Novartis Investigative Site
Melbourne — Australia
Essais liés8clinical trials
VilleMelbournelocalisation
PaysAustralialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07830719
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| INR731 | Cancer | Phase 1 | NCT07570979 | A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer | RECRUITING |
| YMI024 | Maladie coronarienne | Phase 2 | NCT07830719 | Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | RECRUITING |
| AMO959 | Cancer | Phase 1/2 | NCT07226986 | A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | RECRUITING |
| JSB462 | Cancer | Phase 2 | NCT07047118 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | ACTIVE_NOT_RECRUITING |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06675864 | Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS) | ACTIVE_NOT_RECRUITING |
| rapcabtagene autoleucel (YTB323) | SEP | Phase 1/2 | NCT06617793 | An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| EAFToS — Characterizing the Use of Ofatumumab in a Real World Setting | SEP | À vérifier | NCT05090033 | EAFToS — Characterizing the Use of Ofatumumab in a Real World Setting | COMPLETED |